Literature DB >> 6249389

Characteristics of a new binding protein distinct from the kinase for guanosine 3':5'-monophosphate in rat platelets.

J F Coquil, D J Franks, J N Wells, M Dupuis, P Hamet.   

Abstract

A new type of cyclic GMP binding protein was recently identified in our laboratory (Hamet, P. and Coquil, J.-F. (1978) J. Cyclic Nucleotide Res. 4, 281--290). The binding, recovered in the supernatant fractions, is highly specific for cyclic GMP and is clearly distinct from the binding to cyclic GMP-dependent protein kinase. Chromatography on DEAE-Sepharose separated the cyclic GMP binding protein from cyclic AMP binding, cyclic AMP-dependent kinase activities, and from guanylate cyclase. The optimal binding occurs at high pH and in the presence of thiol reagents. Several phosphodiesterase inhibitors increase the affinity of binding (Kd was 353 +/- 60 nM in the absence and 13.4 +/- 1.5 nM in the presence of 1-methyl-3-isobutyl-xanthine). The molecular weight of the binding protein was determined to be about 176,000 and the sedimentation coefficient was 6.4 S. While the binding and phosphodiesterase activities co-migrated on DEAE-Sepharose, gel filtration and sucrose gradients, certain treatments (such as increasing the concentrations of salt and heating) were able to influence one activity while having no effect on the other. Hence, the binding activity may be involved in the regulation of the activity of cyclic GMP phosphodiesterase. Since the binding protein appears to be the only 'receptor' for cyclic GMP detectable in platelets, this protein and/or its relation to cyclic GMP phosphodiesterase may play a role in the mechanism of action of cyclic GMP in platelets.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6249389     DOI: 10.1016/0304-4165(80)90063-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Authors:  Sevil Korkmaz-Icöz; Tamás Radovits; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

2.  Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

Authors:  Rakesh C Kukreja; Fadi N Salloum; Anindita Das; Saisudha Koka; Ramzi A Ockaili; Lei Xi
Journal:  Exp Clin Cardiol       Date:  2011

Review 3.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

4.  Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation.

Authors:  I V Turko; S H Francis; J D Corbin
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

5.  Photoaffinity labelling of cyclic GMP-binding proteins in human platelets.

Authors:  K M Tang; J L Sherwood; R J Haslam
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

6.  PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.

Authors:  Sabrina Noel; Barbara Dhooghe; Teresinha Leal
Journal:  Front Pharmacol       Date:  2012-09-18       Impact factor: 5.810

7.  The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Authors:  Ghazwan Butrous
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

8.  Sildenafil Reduces Neointimal Hyperplasia after Angioplasty and Inhibits Platelet Aggregation via Activation of cGMP-dependent Protein Kinase.

Authors:  Han-Mo Yang; Sooryeonhwa Jin; Hyunduk Jang; Ju-Young Kim; Joo-Eun Lee; Joonoh Kim; Hyo-Soo Kim
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

9.  Vardenafil increases intracellular accumulation of the most prevalent mutant cystic fibrosis transmembrane conductance regulator (CTFR) in human bronchial epithelial cells.

Authors:  Barbara Dhooghe; Caroline Bouzin; Angélique Mottais; Emmanuel Hermans; Martial Delion; Nadtha Panin; Sabrina Noel; Teresinha Leal
Journal:  Biol Open       Date:  2020-08-25       Impact factor: 2.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.